Is Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions
Previous PostExploring the Effects of the European Union (EU) Joint Health Technology Assessment (HTA) on the Launch Sequencing of New Drugs and Identifying Opportunities to Improve the Availability of Reimbursed Medicines in Europe
Next PostThe Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review